Fast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times

Norge Nyheter Nyheter

Fast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times
Norge Siste Nytt,Norge Overskrifter
  • 📰 SFBusinessTimes
  • ⏱ Reading Time:
  • 43 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 68%

Why $ACET is moving quickly with its cell therapy against non-Hodgkin's lymphoma — and taking more space

As Adicet Bio Inc. pushed forward on the path to a potentially pivotal clinical trial, one thing was clear to President and CEOAdicet , which late last year had 87 employees, has hired 44 people since the start of this year as the company tries to prove that its cancer cell therapy not only works but has a durable response in patients.

In June, when Adicet inked the deal for the additional square footage, it had eight patients who could be evaluated and 75% of those had had complete responses, when all detectable cancer is gone. When data came back from the second and third doses of the drug, which is partnered with Regeneron Pharmaceuticals Inc. , 80% of patients had reached that point.

About 80,000 people a year in the United States are diagnosed with NHL. It is treated today with chemotherapy, radiation therapy, bone marrow transplants or other therapies, including other emerging cell therapies. Gamma-delta cells may be the under-appreciated instrument in the fast-moving world of cell therapy development, but while they aren't dangerous, their efficacy and durability isn't proved. But Schor said Adicet is progressing toward that goal.

Vi har oppsummert denne nyheten slik at du kan lese den raskt. Er du interessert i nyhetene kan du lese hele teksten her. Les mer:

SFBusinessTimes /  🏆 78. in US

Norge Siste Nytt, Norge Overskrifter

Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.

Congress hits home stretch renewing FDA user fee programsCongress hits home stretch renewing FDA user fee programsThe FDA could begin sending furlough notices to staff if lawmakers don't settle on a mechanism for reviewing prescription drugs, medical devices, generic drugs and biosimilars.
Les mer »

FDA warns of rare cases of cancers possibly linked to breast implantsFDA warns of rare cases of cancers possibly linked to breast implantsWhile rare, the FDA is warning about certain cancers, including squamous cell carcinoma and various lymphomas, that may develop in scar tissue that forms around breast implants.
Les mer »

FDA Approves Oral TYK2 Inhibitor for Treating PsoriasisFDA Approves Oral TYK2 Inhibitor for Treating PsoriasisDeucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first drug in this class to be approved.
Les mer »

More Than 200 Cases of a Bottled Starbucks Drink Have Been RecalledMore Than 200 Cases of a Bottled Starbucks Drink Have Been RecalledThey may have been contaminated with metal fragments, the FDA said.
Les mer »

FDA approves over-the-counter hearing aids to lower costs, increase accessFDA approves over-the-counter hearing aids to lower costs, increase accessEighty percent of people who would benefit from hearing aids don't wear them, according to the National Institutes of Health. That's because of cost, access and stigma. However, a new move by the FDA may change all of that.
Les mer »

FDA schedules meeting to review over-the-counter birth control pillFDA schedules meeting to review over-the-counter birth control pillThe Food and Drug Administration said it has scheduled a meeting to discuss a proposed birth control pill that would be accessible over the counter.
Les mer »



Render Time: 2025-04-03 20:03:44